Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Bioactive Compounds

Items 9201-9210 of 13616

Page
per page
  1. AG-490
    A4139 AG-490
     3 Citation
    Target: EGFR|JAK
    Summary: JAK2/EGFR inhibitor
      insoluble in H2O; ≥14.7 mg/mL
  2. AZ 960
    A4144 AZ 960
    Target: JAK
    Summary: JAKs inhibitor
      Soluble in DMSO
  3. CI994 (Tacedinaline)
    A4102 CI994 (Tacedinaline)
     1 Citation
    Target: Histone Deacetylases (HDACs)
    Summary: HDAC inhibitor
      insoluble in H2O; insoluble in EtOH; ≥50 mg/mL
  4. Aurora A Inhibitor I
    A4126 Aurora A Inhibitor I
    Target: Aurora Kinases
    Summary: Aurora A inhibitor
      ≥29.4 mg/mL
  5. Aminophylline
    A4346 Aminophylline
    Target: Phosphodiesterases (PDEs)
    Summary: Pan-PDE inhibitor
      ≥13.48 mg/mL
  6. Delafloxacin meglumine
    A3357 Delafloxacin meglumine
    Summary: Fluoroquinolone antibiotic agent
      ≥51.7 mg/mL
  7. Rotigotine hydrochloride
    A3777 Rotigotine hydrochloride
    Summary: Agonist of dopamine D2/D3 receptor
      ≥21.2 mg/mL
  8. Vinorelbine ditartrate
    A3921 Vinorelbine ditartrate
    Summary: Anti-mitotic chemotherapy drug
      ≥33.7 mg/mL
  9. Mal-PEG2-acid
    BA2464 Mal-PEG2-acid
    Summary: Mal-PEG2-acid can be used to synthesize antibody-coupled active molecules (ADCs).
  10. AZ31
    BA3716 AZ31
    Summary: AZ31 is a potent, highly selective, orally active inhibitor.

Items 9201-9210 of 13616

Page
per page